CATALYSTYahoo • 1d ago
Ligand Pharmaceuticals Sees Strong Royalty Growth Ahead of Investor Day, Oppenheimer SaysLigand Pharmaceuticals (LGND) raised its 2026 adjusted EPS guidance but maintained its royalty and t
Why LGND Stock slipped -0.45% Today — RQD Quant Desk Flash
$317.33 -0.45% NASDAQ • Public Delayed / 60s Snapshot
Ligand Pharmaceuticals Incorporated (LGND) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (56/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+269.1% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
ROARABLE D+ • SELL / AVOID
Cap $6.33B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS TUG-OF-WAR:57% Call Buyers ($2.6M)
43% PutsMax Pain: $311.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LGND Stock slipped -0.45% Today — RQD Quant Desk Flash
Ligand Pharmaceuticals Incorporated (LGND) slipped -0.45% to $317.33 as options desks priced 57% call premium vs. 43% put protection around the $311 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+269.1% (NI vs OCF)) as receivables rose.
- ▸Technical Tape: Trading at 94% of its 52-week range ($175.89 – $326.63) with RSI-14 at 63.4 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $2.6M in bullish call flow vs. $1.9M in put flow (Put/Call 0.74x, implied earnings swing ±7.1%).
- ▸Primary SEC / Cross-Feed Trigger: LGND Accounting Gap: Net Income (+220%) Outpaced OCF (-49.1%) With +93.2% Working-Capital Build
Live LGND Headlines & Catalysts
RISK WATCHYahoo • 1d ago
Ligand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty StrengthLigand Pharmaceuticals just posted Q3 2026 results, and the story the numbers tell is very different from the mood on the screen. The stock is up about 1.2% in Friday trading, a calm reaction for a quarter that paired a
CATALYSTYahoo • 1d ago
Ligand (LGND) Q3 2026 Earnings Call TranscriptRoyalty revenue surged 51% on XOMA acquisition and Filspari momentum.
MARKET WIREYahoo • 1d ago
Ligand Pharmaceuticals Incorporated Q3 2026 Earnings Call SummaryMoby summary of Ligand Pharmaceuticals Incorporated's Q3 2026 earnings call
CATALYSTBenzinga • 1d ago
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.
MARKET WIRESeekingAlpha • 1d ago
Ligand Pharmaceuticals Incorporated 2026 Q3 - Results - Earnings Call Presentation2026-10-30. The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with their 2026 Q3 earnings call.
RISK WATCHSeekingAlpha • 2d ago
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call TranscriptLigand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDTCompany ParticipantsMelanie Herman - Executive Director of...
CATALYSTYahoo • 2d ago
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings CallLigand Pharmaceuticals (NASDAQ:LGND) reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired through its July purchas
RISK WATCHYahoo • 2d ago
Ligand: Q3 Earnings Snapshot(AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $28.
CATALYSTYahoo • 2d ago
Ligand Reports Third Quarter 2026 Financial ResultsThird-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.501; Reaffirms Revenue Guidance Conference call begins at 8:30
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring LGND)
- ✓Live walkthrough of LGND's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
LGND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +40.66%▲ RESISTANCE BREAKOUT
2026-10-30O $319.2H $324.9L $314.5C $322.8VOL 344.3K
RES: $317.1SUP: $255.1SMA50: $296.4SMA200: $252.7
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LGND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
36.8%/yr Implied 5Y Growth
vs. +60.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LGND today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LGND. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LGND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
LGND Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LGND stock moving today?
Why LGND Stock slipped -0.45% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+269.1% (NI vs OCF)) as receivables rose.